Cytek Biosciences Inc (CTKB)
Debt-to-capital ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 395,737 | 393,064 | 425,295 | 406,458 | -16,028 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | — |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $395,737K)
= 0.00
The debt-to-capital ratio of Cytek Biosciences Inc has shown a consistent trend of 0.00 since December 31, 2021 through December 31, 2024. This indicates that the company has not utilized debt as a significant portion of its capital structure during these years. A debt-to-capital ratio of zero suggests that the company is primarily financed through equity rather than debt, which can be a positive sign of financial stability and lower financial risk. This may indicate that Cytek Biosciences Inc has a strong financial position and may potentially be in a favorable position to pursue growth opportunities or weather economic downturns without being heavily burdened by debt obligations.
Peer comparison
Dec 31, 2024